Table 1. Baseline characteristics.
| Characteristics | (All Patients: N = 559) | |
|---|---|---|
| Age (years); median (IQR) | 35 (30–41) | |
| Female gender; n (%) | 386 (69.0) | |
| BMI (kg/m2); median (IQR) | 20 (18–22) | |
| WHO Stage | ||
| I/II; n (%) | 62 (11.1) | |
| III/IV; n (%) | 497 (88.9) | |
| CD4 cell count (cells/μl) | ||
| Median (IQR) | 98 (21–163) | |
| <50; n (%) | 198 (35.8) | |
| 50–100; n (%) | 94 (17.0) | |
| >100; n (%) | 261 (47.2) | |
| Viral load (log10 copies/mL); median (IQR) | 5.4 (5.1–5.8) | |
| Hemoglobin level (g/dl); median (IQR) | 11.5 (10.3–12.9) | |
| ART regimen | ||
| Nevirapine-based; n (%) | 414 (74.1) | |
| Efavirenz-based; n (%) | 145 (25.9) | |
ART: antiretroviral therapy; BMI: body mass Index; IQR: interquartile range; WHO: World Health Organization